Rosetta Genomics last week said that it has received commitments from institutional investors to purchase roughly $5.1 million of its securities in a registered direct offering.
Rosetta Genomics last week said that it has received commitments from institutional investors to purchase roughly $5.1 million of its securities in a registered direct offering.
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.